WHO 2016 Classification of gliomas

Neuropathology and Applied Neurobiology - Tập 44 Số 2 - Trang 139-150 - 2018
Pieter Wesseling1,2, David Capper3,4,4
1Department of Pathology Princess Máxima Center for Pediatric Oncology University Medical Center Utrecht Utrecht The Netherlands
2Department of Pathology, Brain Tumor Center Amsterdam/VU University Medical Center, Amsterdam, The Netherlands
3Charité ‐Universitätsmedizin Berlin corporate member of Freie Universität Berlin, Humboldt‐Universität zu Berlin, and Berlin Institute of Health Department of Neuropathology Berlin Germany
4German Cancer Research Center (DKFZ) Clinical Cooperation Unit Neuropathology German Cancer Consortium (DKTK) Heidelberg Germany

Tóm tắt

Abstract

Gliomas are the most frequent intrinsic tumours of the central nervous system and encompass two principle subgroups: diffuse gliomas and gliomas showing a more circumscribed growth pattern (‘nondiffuse gliomas’). In the revised fourth edition of the WHO Classification of CNS tumours published in 2016, classification of especially diffuse gliomas has fundamentally changed: for the first time, a large subset of these tumours is now defined based on presence/absence of IDH mutation and 1p/19q codeletion. Following this approach, the diagnosis of (anaplastic) oligoastrocytoma can be expected to largely disappear. Furthermore, in the WHO 2016 Classification gliomatosis cerebri is not an entity anymore but is now considered as a growth pattern. The most important changes in the very diverse group of ‘nondiffuse’ gliomas and neuronal‐glial tumours are the introduction of anaplastic pleomorphic xanthoastrocytoma, of diffuse leptomeningeal glioneuronal tumour and of RELA fusion‐positive ependymoma as entities. In the last part of this review, after very briefly touching upon classification of neuronal, choroid plexus and pineal region tumours, some practical implications and challenges associated with the WHO 2016 Classification of gliomas are discussed.

Từ khóa


Tài liệu tham khảo

Louis DN, 2007, WHO Classification of Tumours of the Central Nervous System

10.1111/bpa.12171

Louis DN, 2016, WHO Classification of Tumours of the Central Nervous System

10.1016/B978-0-12-802997-8.00005-0

10.1126/science.1164382

10.1007/s00401-008-0455-2

10.1056/NEJMoa0808710

10.1200/JCO.2009.21.9832

10.1158/1078-0432.CCR-10-3194

10.1007/s00401-015-1454-8

10.1056/NEJMoa1402121

10.1212/WNL.0b013e3181e1cf3a

10.1007/s00401-014-1370-3

10.1007/s00401-014-1326-7

10.1056/NEJMoa1407279

10.1038/ng.3273

10.1007/s00401-014-1359-y

10.1007/s00401-014-1353-4

10.1007/s00401-016-1545-1

10.1158/1078-0432.CCR-12-3002

Hinrichs BH, 2016, Farewell to GBM‐O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups, Acta Neuropathol Commun, 4, 4, 10.1186/s40478-015-0270-7

10.1097/PAS.0b013e31827f9c5e

10.1038/nature10833

10.1038/ng.2938

10.1007/s00401-015-1405-4

10.1111/bpa.12336

10.1111/nan.12371

10.1093/neuonc/now274

10.1007/s00401-015-1478-0

10.1007/s00401-016-1608-3

10.1111/nan.12329

López G, 2017, Diffuse non‐midline glioma with H3F3A K27M mutation: A prognostic and treatment dilemma, Acta Neuropathol Commun, 5, 38, 10.1186/s40478-017-0440-x

10.1007/s00401-015-1495-z

10.1186/1477-5751-10-7

10.1007/s00401-016-1643-0

10.1007/s00401-015-1410-7

10.1016/j.ccell.2015.04.002

10.1038/nature13109

10.1038/ng.3500

10.1016/j.cell.2016.01.015

10.1007/s00401-015-1400-9

10.1111/bpa.12035

10.1111/bpa.12282

10.1093/jnen/nlv009

10.1007/s00401-015-1424-1

10.1097/PAS.0000000000000221

10.1007/s00401-015-1398-z

10.1007/s00401-015-1438-8

10.1007/s00401-016-1646-x

Thông tin
Thông tin xuất bản

Neuropathology and Applied Neurobiology

Tập 44 Số 2

139-150

Thông tin tác giả